Meta-analysis: rectal indomethacin for the prevention of post-ERCP pancreatitis

被引:48
作者
Yaghoobi, M. [1 ,2 ,3 ]
Rolland, S. [4 ]
Waschke, K. A. [1 ]
McNabb-Baltar, J. [1 ,5 ]
Martel, M. [1 ]
Bijarchi, R. [1 ]
Szego, P. [1 ]
Barkun, A. N. [1 ]
机构
[1] McGill Univ Hlth Sci, Div Gastroenterol, Montreal, PQ, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Gastroenterol, Montreal, PQ H3T 1E2, Canada
[3] Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA
[4] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; STENT PLACEMENT; DUCT STENTS; PROPHYLAXIS; SEVERITY; DAMAGE; TRIAL;
D O I
10.1111/apt.12488
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundDespite initial evidence in the literature, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been widely used to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). AimTo complete a meta-analysis of high-quality RCTs that included the latest available literature published after past meta-analytical efforts MethodsA comprehensive electronic literature search was carried out for RCTs comparing peri-procedural rectal indomethacin and placebo in preventing PEP. Methodological quality was assessed by the Cochrane risk of bias tool. Fixed model Mantel-Haenszel meta-analysis, Q test and I-2 index were used. Several subgroup and sensitivity analyses were planned. ResultsA total of four of 61 retrieved trials between 2007 and 2012 (n=1470) were included. No significant publication bias existed. All studies used similar criteria to detect pancreatitis. The pooled proportion estimate of the rate of pancreatitis was 5.1% with indomethacin and 10.3% with placebo. After excluding the high-risk patients, the rates were 3.9% and 7.9% respectively. Fixed model meta-analysis showed that the rate of pancreatitis was significantly lower using indomethacin as compared with placebo [OR=0.49(0.34-0.71); P=0.0002]. Number needed to treat was 20. There was no significant statistical or clinical heterogeneity. In subgroup analysis, the difference remained unchanged for average-risk population [OR=0.49(0.28-0.85); P=0.01] or in preventing severe PEP [OR=0.41(0.21-0.78); P=0.007]. The result of the main outcome remained robust in multiple sensitivity analyses. ConclusionsRectal indomethacin used immediately before or after ERCP significantly reduces the risk of PEP to half in both low- and high-risk patients, and with both statistically and clinically significant conclusions. These results suggest that a possible change in routine practice for patients at both low and high risk of developing PEP should be advocated.
引用
收藏
页码:995 / 1001
页数:7
相关论文
共 28 条
[1]   Rectal Nonsteroidal Anti-inflammatory Drugs Are Superior to Pancreatic Duct Stents in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Network Meta-analysis [J].
Akbar, Ali ;
Abu Dayyeh, Barham K. ;
Baron, Todd H. ;
Wang, Zhen ;
Altayar, Osama ;
Murad, Mohammad Hassan .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (07) :778-783
[2]  
Alderson P., 2002, COCHRANE COLLABORATI
[3]   Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: A systematic analysis of benefits and associated risks [J].
Andriulli, Angelo ;
Forlano, Rosario ;
Napolitano, Grazia ;
Conoscitore, Pasquale ;
Caruso, Nazario ;
Pilotto, Alberto ;
Di Sebastiano, Pier Luigi ;
Leandro, Gioacchino .
DIGESTION, 2007, 75 (2-3) :156-163
[4]   Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial [J].
Arvanitidis, D ;
Anagnostopoulos, GK ;
Giannopoulos, D ;
Pantes, A ;
Agaritsi, R ;
Margantinis, G ;
Tsiakos, S ;
Sakorafas, G ;
Kostopoulos, P .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (03) :278-282
[5]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[6]   Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography [J].
Cavallini, G ;
Tittobello, A ;
Frulloni, L ;
Masci, E ;
Mariani, A ;
DiFrancesco, V ;
Angelini, GP ;
Casarini, MB ;
Bedogni, G ;
Conigliaro, R ;
Bonardi, L ;
Khajekini, MTA ;
Cipolletta, L ;
Bianco, MA ;
Costamagna, G ;
Perri, V ;
Dobrilla, G ;
DePretis, G ;
Familiari, L ;
Giacobbe, G ;
Fratton, A ;
Carone, N ;
Loriga, P ;
Muscas, A ;
Mazzeo, F ;
Gaeta, L ;
Miglioli, M ;
Pezzilli, R ;
Morelli, A ;
Santucci, L ;
Naccarato, R ;
DelFavero, G ;
Orlandi, F ;
Macarri, GP ;
Russo, A ;
Virgilio, C ;
Uomo, G ;
Manes, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (13) :919-923
[7]   Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review [J].
Choudhary, Abhishek ;
Bechtold, Matthew L. ;
Arif, Murtaza ;
Szary, Nicholas M. ;
Puli, Srinivas R. ;
Othman, Mohamed O. ;
Pais, Wilson P. ;
Antillon, Mainor R. ;
Roy, Praveen K. .
GASTROINTESTINAL ENDOSCOPY, 2011, 73 (02) :275-282
[8]  
Dai HF, 2009, HEPATOB PANCREAT DIS, V8, P11
[9]   Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis [J].
Das, Ananya ;
Singh, Pankaj ;
Sivak, Michael V., Jr. ;
Chak, Arnitabh .
GASTROINTESTINAL ENDOSCOPY, 2007, 65 (07) :960-968
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188